EBAC Accredited symposium held on August 31 during ESC 2015, London, UK

Teaching slides posted below.

Inflammation in Acute Myocardial Infarction & Ventricular Remodelling

Dr. Matthias Nahrendorf,
Boston, MA, USA

Inflammation and Thrombosis

Dr. Raffaele De Caterina,
Chieti, Italy


 

 

Inflammation as target for therapy in atherothrombosis

Dr. Prof. Paul Ridker
Boston, MA, USA


 

Educational objectives

• Review new insights into the influence of inflammatory leukocytes and cytokines on the repair of acute myocardial ischemic injury and on left ventricular remodeling and healing
• Review the current evidence implicating inflammation in promoting thrombosis and inhibiting endogenous thrombolysis
• Discuss the rationale for lowering vascular events by inhibition of inflammation
• Discuss the potential of current and future strategies targeting inflammation in cardiovascular disease such as methotrexate, colchicine,  and inhibition of IL-1 beta and MAP kinases
• Outline current ongoing clinical development programs aimed at testing the inflammation hypothesis of cardiovascular disease

 

Educational programme & downloadable teaching slides

Co-Chairmen:
Peter Libby, MD - Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
Thomas F Lüscher  MD - University Hospital Zurich, Zurich, Switzerland
 

Inflammation in Acute Myocardial Infarction & Ventricular Remodelling

Teaching slides prepared and presented by Dr. Matthias Nahrendorf,Boston, USA at EBAC accredited symposium ' Cytokines and Cardiovascular disease: Exploring Inflammation & Clinical Outcomes'.
 

Inflammation and Thrombosis

Teaching slides prepared and presented by Dr. Raffaele De Caterina, Chieti, Italy at EBAC accredited symposium ' Cytokines and Cardiovascular disease: Exploring Inflammation & Clinical Outcomes'
 

Inflammation as target for therapy in atherothrombosis

Teaching slides prepared and presented by Prof Paul M Ridker, Boston, USA, Italy at EBAC accredited symposium ' Cytokines and Cardiovascular disease: Exploring Inflammation & Clinical Outcomes'.
 

Financial support

Supported by an unrestricted educational grant from Novartis Pharma AG